Back to mobile site
Get it on Google Play

Bristol Myers Squibb lung fibrosis drug meets Phase 3 trial goal

October 12, 2026 6:50 AM EDT Send to a Friend
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login